Now the hard work really begins.
AstraZeneca's (NYSE: AZN )
SGLT-2 inhibitor dapaglifozin has had a difficult path to market, but
the company finally got the FDA's go-ahead to market the drug on
Wednesday. While SGLT-2 inhibitors are a promising new class of drug, it
remains to be seen whether AstraZeneca's Farxiga (it's U.S. brand name)
can become a blockbuster in the face of competition from Johnson & Johnson's (NYSE: JNJ ) first-to-market Invokana and follow-on drugs from Lilly (NYSE: LLY ) and Astellas.
Please follow this link:
AstraZeneca plc (ADR) Hopes Farxiga Can Go Far
No comments:
Post a Comment